Pfenex Inc (PFNX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

10790 ROSELLE STREET SAN DIEGO, CA 92121

Pfenex Inc. provides clinical-stage biotechnology products. The Company offers high-value proteins and biosimilar therapeutics.

Data as of 2019-12-03 01:27:15 -0500
Market Cap316.443 Million Shares Outstanding31.676 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-0.478
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low11.39 / 3.13 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from PFNX instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 2 -100.0% 0 (0.0%) 2 (0.12%) -100.0%
Funds Holding: 1 56 -98.21% (0.0%) 21 (1.31%)
13F shares: 58.304 Thousand 24.093 Million -99.76% 0 17.486 Million -100.0%
% Ownership
New Positions: 22 13
Increased Positions 1 8 -87.5% 3
Closed Positions 54 51 5.88% 21 24 -12.5%
Reduced Positions 20 4
Total Calls 0 5.6 Thousand -100.0% 0
Total Puts 0 770.012 Thousand -100.0% 0 396.3 Thousand -100.0%
PUT/CALL Ratio 137.5
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding PFNX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PFNX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LUCY PATRICK K. CHIEF BUSINESS OFFICER

  • Officer
0 2020-10-01 2

SCHNEIDER PHILLIP M

  • Director
0 2020-10-01 1

CAMPBELL ROBIN

  • Director
0 2020-10-01 1

TAYLOR JOHN MACK

  • Director
0 2020-10-01 1

GRENFELL-GARDNER JASON

  • Director
0 2020-10-01 1

SCHIMMELPENNINK EVERT B. SEE REMARKS

  • Officer
  • Director
0 2020-10-01 1

SCRANTON SHAWN CHIEF OPERATING OFFICER

  • Officer
0 2020-10-01 1

MARQUET MAGDA

  • Director
0 2020-10-01 1

BRENNER MARTIN CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-10-01 1

MASUOKA LORIANNE

  • Director
0 2020-10-01 1

LIGAND PHARMACEUTICALS INC

  • 10% Owner
27,034,437 2020-10-01 1

WEISS ASSET MANAGEMENT LP

WEISS ANDREW M

WAM GP LLC

  • 10% Owner
3,418,631 2020-09-30 3

NEWTYN MANAGEMENT, LLC

  • 10% Owner
0 2020-09-30 2

OLAFSSON SIGURDUR O

  • Director
0 2019-05-09 0

KNUDSON SUSAN A. CHIEF FINANCIAL OFFICER

  • Officer
0 2019-02-01 0

LADY PATRICIA CHIEF ACCOUNTING OFFICER

  • Officer
0 2018-02-01 0

CHEN HUBERT C SEE REMARKS

  • Officer
0 2018-02-01 0

FENTON DENNIS M

  • Director
0 2017-05-05 0

WAGNER PAUL A. CHIEF FINANCIAL OFFICER

  • Officer
0 2017-03-01 0

SIGNET HEALTHCARE PARTNERS ACCREDITED PARTNERSHIP III LP

  • 10% Owner
556,656 2017-01-06 0

SANDOVAL STEVEN S. SR. CHIEF MANUFACTURING OFFICER

  • Officer
0 2016-10-03 0

ROHN WILLIAM R

  • Director
0 2016-05-06 0

TALBOT HENRY W. JR. VP OF OPERATIONS

  • Officer
0 2016-02-01 0

LIANG BERTRAND C. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2016-02-01 0

DOW CHEMICAL CO /DE/

  • 10% Owner
2,221,428 2015-12-15 0

GALE JAMES C

  • Director
No longer subject to file 2015-04-29 0

SIGNET HEALTHCARE PARTNERS ACCREDITED PARTNERSHIP III LP

SIGNET HEALTHCARE PARTNERS QP PARTNERSHIP II LP

  • 10% Owner
3,395,147 2014-07-29 0

VAN HEEL KENNETH

  • Director
0 2014-07-17 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments